B-intervention	0	7	Nevasic
I-intervention	8	13	audio
I-intervention	14	21	program
O	22	25	for
O	26	29	the
O	30	40	prevention
O	41	43	of
B-condition	44	56	chemotherapy
I-condition	57	64	induced
I-condition	65	71	nausea
I-condition	72	75	and
I-condition	76	84	vomiting
O	84	85	:
O	86	87	A
O	88	99	feasibility
O	100	105	study
O	106	111	using
O	112	113	a
O	114	124	randomized
O	125	135	controlled
O	136	141	trial
O	142	148	design
O	148	149	.

O	150	165	Pharmacological
O	166	173	therapy
O	174	176	is
O	177	181	only
O	182	191	partially
O	192	201	effective
O	202	204	in
O	205	215	preventing
O	216	218	or
O	219	227	treating
O	228	240	chemotherapy
O	241	248	induced
O	249	255	nausea
O	256	259	and
O	260	268	vomiting
O	269	270	(
O	270	274	CINV
O	274	275	)
O	275	276	.

O	277	286	Therefore
O	286	287	,
O	288	297	exploring
O	298	301	the
O	302	315	complementary
O	316	320	role
O	321	323	of
O	324	327	non
O	327	328	-
O	328	343	pharmacological
O	344	354	approaches
O	355	359	used
O	360	362	in
O	363	371	addition
O	372	374	to
O	375	390	pharmacological
O	391	397	agents
O	398	400	is
O	401	410	important
O	410	411	.

O	412	419	Nevasic
O	420	424	uses
O	425	434	specially
O	435	446	constructed
O	447	452	audio
O	453	460	signals
O	461	473	hypothesized
O	474	476	to
O	477	485	generate
O	486	488	an
O	489	499	antiemetic
O	500	508	reaction
O	508	509	.

O	510	513	The
O	514	517	aim
O	518	520	of
O	521	525	this
O	526	531	study
O	532	535	was
O	536	538	to
O	539	546	examine
O	547	550	the
O	551	562	feasibility
O	563	565	of
O	566	576	conducting
O	577	578	a
O	579	589	randomized
O	590	600	controlled
O	601	606	trial
O	607	608	(
O	608	611	RCT
O	611	612	)
O	613	615	to
O	616	624	evaluate
O	625	628	the
O	629	642	effectiveness
O	643	645	of
O	646	653	Nevasic
O	654	656	to
O	657	664	control
O	665	669	CINV
O	669	670	.

O	671	672	A
O	673	678	mixed
O	679	686	methods
O	687	693	design
O	694	707	incorporating
O	708	710	an
O	711	714	RCT
O	715	718	and
O	719	724	focus
O	725	730	group
O	731	741	interviews
O	741	742	.

O	743	746	For
O	747	750	the
O	751	754	RCT
O	754	755	,
B-eligibility	756	762	female
I-eligibility	763	769	breast
I-eligibility	770	776	cancer
I-eligibility	777	785	patients
O	786	790	were
O	791	801	randomized
O	802	804	to
O	805	812	receive
O	813	819	either
O	820	827	Nevasic
O	828	832	plus
O	833	838	usual
O	839	843	care
O	843	844	,
O	845	850	music
O	851	855	plus
O	856	861	usual
O	862	866	care
O	866	867	,
O	868	870	or
B-control	871	876	usual
I-control	877	881	care
I-control	882	886	only
O	886	887	.

O	888	892	Data
O	893	897	were
O	898	906	analysed
O	907	912	using
O	913	924	descriptive
O	925	935	statistics
O	936	939	and
O	940	946	linear
O	947	952	mixed
O	952	953	-
O	953	960	effects
O	961	967	models
O	967	968	.

O	969	973	Five
O	974	979	focus
O	980	985	group
O	986	996	interviews
O	997	1001	were
O	1002	1011	conducted
O	1012	1014	to
O	1015	1021	obtain
O	1022	1034	participants
O	1034	1035	'
O	1036	1041	views
O	1042	1051	regarding
O	1052	1055	the
O	1056	1069	acceptability
O	1070	1072	of
O	1073	1076	the
O	1077	1090	interventions
O	1091	1093	in
O	1094	1097	the
O	1098	1103	trial
O	1103	1104	.

B-total-participants	1105	1107	99
O	1108	1120	participants
O	1121	1125	were
O	1126	1135	recruited
O	1136	1138	to
O	1139	1142	the
O	1143	1146	RCT
O	1147	1150	and
B-total-participants	1151	1153	15
O	1154	1166	participated
O	1167	1169	in
O	1170	1175	focus
O	1176	1181	group
O	1182	1192	interviews
O	1192	1193	.

O	1194	1205	Recruitment
O	1206	1213	targets
O	1214	1218	were
O	1219	1227	achieved
O	1227	1228	.

O	1229	1235	Issues
O	1236	1238	of
O	1239	1246	Nevasic
O	1247	1260	acceptability
O	1261	1265	were
O	1266	1277	highlighted
O	1278	1280	as
O	1281	1291	weaknesses
O	1292	1294	of
O	1295	1298	the
O	1299	1306	program
O	1306	1307	.

O	1308	1312	This
O	1313	1318	study
O	1319	1322	did
O	1323	1326	not
O	1327	1333	detect
O	1334	1337	any
O	1338	1346	evidence
O	1347	1350	for
O	1351	1354	the
O	1355	1368	effectiveness
O	1369	1371	of
O	1372	1379	Nevasic
O	1379	1380	;
O	1381	1388	however
O	1388	1389	,
O	1390	1393	the
O	1394	1401	results
O	1402	1408	showed
O	1409	1422	statistically
O	1423	1434	significant
O	1435	1439	less
B-outcome	1440	1443	use
I-outcome	1444	1446	of
I-outcome	1447	1451	anti
I-outcome	1451	1452	-
I-outcome	1452	1459	emetics
O	1460	1461	(
O	1461	1462	p
O	1463	1464	=
O	1465	1466	0
O	1466	1467	.
O	1467	1470	003
O	1470	1471	)
O	1472	1475	and
O	1476	1486	borderline
O	1487	1490	non
O	1490	1491	-
O	1491	1502	significant
O	1503	1514	improvement
O	1515	1517	in
B-outcome	1518	1525	quality
I-outcome	1526	1528	of
I-outcome	1529	1533	life
O	1534	1535	(
O	1535	1536	p
O	1537	1538	=
O	1539	1540	0
O	1540	1541	.
O	1541	1543	06
O	1543	1544	)
O	1544	1545	.

O	1546	1556	Conducting
O	1557	1558	a
O	1559	1562	non
O	1562	1563	-
O	1563	1578	pharmacological
O	1579	1591	intervention
O	1592	1597	using
O	1598	1602	such
O	1603	1605	an
O	1606	1611	audio
O	1612	1619	program
O	1620	1622	is
O	1623	1631	feasible
O	1631	1632	,
O	1633	1641	although
O	1642	1654	difficulties
O	1655	1658	and
O	1659	1670	limitations
O	1671	1676	exist
O	1677	1681	with
O	1682	1685	its
O	1686	1689	use
O	1689	1690	.

O	1691	1698	Further
O	1699	1706	studies
O	1707	1710	are
O	1711	1719	required
O	1720	1722	to
O	1723	1734	investigate
O	1735	1738	the
O	1739	1752	effectiveness
O	1753	1755	of
O	1756	1763	Nevasic
O	1764	1768	from
O	1769	1781	perspectives
O	1782	1786	such
O	1787	1789	as
O	1790	1794	anti
O	1794	1795	-
O	1795	1801	emetic
O	1802	1805	use
O	1805	1806	,
O	1807	1809	as
O	1810	1814	well
O	1815	1817	as
O	1818	1821	its
O	1822	1829	overall
O	1830	1836	effect
O	1837	1839	on
O	1840	1843	the
O	1844	1850	levels
O	1851	1853	of
O	1854	1860	nausea
O	1861	1864	and
O	1865	1873	vomiting
O	1873	1874	.
